3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
80
Nivolumab
60
Sunitinib
59
Sorafenib
36
Everolimus
32
pazopanib
30
Axitinib
27
cabozantinib
25
Ipilimumab
24
Bevacizumab
24
atezolizumab
20
belzutifan
19
lenvatinib
16
avelumab
13
Paclitaxel
10
Docetaxel
9
temsirolimus
8
Cyclophosphamide
8
spartalizumab
7
fludarabine
7
Interleukin-2
7
Interferon alpha-2
7
tivozanib
6
durvalumab
6
Cetuximab
6
cemiplimab
5
aldesleukin
5
Ramucirumab
5
CB-839
5
bempegaldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Renal Cell
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled